Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Godavari DrugsBOM:530317 -0.49%54 PEG Ratio is 3.47 as of Aug. 12, 2026, which is 48% above its 10-year median of 2.34. GuruFocus rates BOM:530317 with a GF Score™ of 54/100 and a GF Value™ of ₹72.35 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 345 Drug Manufacturers companies, Godavari Drugs ranks worse than 71.59% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Godavari Drugs's PEG Ratio or its related term are showing as below:
BOM:530317'
s PEG Ratio Range Over the Past 10 Years
Min: 0.42 Med: 2.34 Max: 51.34
Current: 3.47
During the past 13 years, Godavari Drugs's highest PEG Ratio was 51.34. The lowest was 0.42. And the median was 2.34.
BOM:530317's PEG Ratio is ranked worse than 71.59% of 345
companies
in the Drug Manufacturers industry
Industry Median: 1.78
vs BOM:530317: 3.47
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Godavari Drugs PEG Ratio Related Terms
Godavari Drugs PEG Ratio Historical Data
* Premium members only.
The historical data trend for Godavari Drugs's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Godavari Drugs's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Godavari Drugs PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Godavari Drugs's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Godavari Drugs's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Godavari Drugs (BOM:530317) has a PEG Ratio of 3.47 as of Aug. 12, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Godavari Drugs and its competitors. This is 48% above median its historical median of 2.34. Over the past decade, Godavari Drugs' PEG Ratio has ranged from 0.42 to 51.34. According to the industry distribution chart, Godavari Drugs ranks #247 out of 345 companies in the Drug Manufacturers industry, placing it in the top 71.6%.
Is Godavari Drugs' PEG Ratio too high?
Godavari Drugs' current PEG Ratio of 3.47 is 48% above median its 10-year median of 2.34. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 51.34. The Drug Manufacturers industry median PEG Ratio is 1.78. Godavari Drugs' value of 3.47 is 94.9% above this industry median. Based on the distribution chart, Godavari Drugs ranks #247 out of 345 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Godavari Drugs has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Godavari Drugs' PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Godavari Drugs ranks #247 out of 345 companies for PEG Ratio. This places Godavari Drugs in the lower half of its industry. The industry median PEG Ratio is 1.78. Godavari Drugs' value of 3.47 is 94.9% above this benchmark. Historically, Godavari Drugs' own PEG Ratio has ranged from 0.42 to 51.34 over the past decade. While the company's 10-year median is 2.34 vs. the industry median of 1.78, Godavari Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.78, based on 345 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Godavari Drugs's current PEG Ratio of 3.47 is 94.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Godavari Drugs and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Godavari Drugs's current PEG Ratio is 3.47, which is 48% above median its own 10-year median of 2.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Godavari Drugs stock overvalued right now?
Based on GuruFocus' analysis, Godavari Drugs (BOM:530317) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹72.35, compared to a current price of ₹102.50 — trading 41.7% above its estimated fair value. The current PEG Ratio is 3.47, which is 48% above median its 10-year median of 2.34 and 94.9% above the Drug Manufacturers industry median of 1.78. Godavari Drugs' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Godavari Drugs (BOM:530317), the current PEG Ratio is 3.47 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Godavari Drugs (BOM:530317) Overvalued in 2026?
Based on GuruFocus' analysis, Godavari Drugs stock appears to be overvalued.
The current stock price of ₹102.50 is trading 41.7% above its estimated GF Value™ of ₹72.35.
GuruFocus considers Godavari Drugs to be Significantly Overvalued.
Key valuation signals for BOM:530317:
PEG Ratio: 3.47 (48% above median its 10-year median of 2.34)
GF Value™: ₹72.35 vs. price of ₹102.50 (41.7% above fair value)
Industry Position: 94.9% above the Drug Manufacturers median (#247 of 345)
No single metric tells the full story. See the BOM:530317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Godavari Drugs Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing of APl's, intermediates and fine chemicals,. The firm's product includes Ciprofloxacin hydrochloride, ciprofloxacin, ciprofloxacin lactate, ciprofloxacin lactate, and Others. The company operates only one segment which is the manufacture and sale of Active Pharmaceutical Ingredients (API) and its intermediates.
54GF Score
Get the complete analysis for BOM:530317
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530317 has been successfully added to your 
